GET THE APP

GALDERMA – Staying competitive in dermatology drug R&D in a world where disease knowledge and technology development are evolving rapidly | SciTechnol

Clinical Dermatology Research Journal.ISSN: 2576-1439

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Short Communication, Clin Dermatol Res J Vol: 5 Issue: 4

GALDERMA – Staying competitive in dermatology drug R&D in a world where disease knowledge and technology development are evolving rapidly

 

 

Abstract


 Large biotech companies with a dermatology department generally harbor skills in large molecule development (i.e., monoclonal antibodies / mAbs) but never meet more than 20% of practicing dermatologists globally as a result. In contrast and by nature, dermatology start-up companies come to life with a product or products generated from a unique technology base that reflects either mAb or small molecular entity (SME) expertise; they may succeed by being acquired or by taking a long time to evolve. Historically, legacy pure dermatology players have started with similar limitations, but staying competitive has required them to add a new technology capability to their in-house expertise through either time- and resource-consuming FTE growth or M&A activity, and there are few such legacy derm companies remaining in the world. At Galderma, we have developed a new model for conducting dermatology research – one that allows us to: 1) address any unmet medical need with the most suitable technology required without waiting to grow in-house expertise or finance M&A; 2) double the resources we can invest in new projects; and 3) maintain our service to dermatologists throughout the world – whether they focus on mild disorders or the most severe, life-threatening diseases known in dermatology. In a world where disease knowledge and technology development are evolving at a pace at which others struggle to keep up, Galderma has found a way to ensure that the manufacturer need never be the rate-limiting step in bringing leading edge solutions to the prevention, treatment, or cure of dermatologic disorders.
 

Keywords: Dermatology drug R&D, Clinical Dermatology

Track Your Manuscript

Google scholar citation report
Citations : 34

Clinical Dermatology Research Journal received 34 citations as per google scholar report

Media Partners

Associations